{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.7","upperLimit":"26","value":"15"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"}],"units":"Participants"}],"dispersionType":"Full Range","groups":[{"description":"A cycle of therapy consisted of bortezomib 1.3 mg/m(2) intravenously; dexamethasone 40 mg on days 1, 4, 8, and 11; and rituximab 375 mg/m(2) on day 11. Patients received four consecutive cycles for induction therapy and then four more cycles, each given 3 months apart, for maintenance therapy.\n\nBortezomib: Given intravenously on days 1, 4, 8, and 11 of a 21-day cycle for 8 cycles\n\nDexamethasone: Given intravenously on days 1, 4, 8, and 11 of a 21-day cycle for 8 cycles\n\nRituximab: Given intravenously after bortezomib and dexamethasone on day 11 of a 21-day cycle for 8 cycles","id":"OG000","title":"Bortezomib, Dexamethasone, Rituximab"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"33.2 months","title":"Time to Best Response","type":"PRIMARY","unitOfMeasure":"Months"}